The National Institutes of Health (NIH) is launching a program that will shepherd drug candidates aimed at treating rare and neglected diseases through the most challenging phase of drug development.
The program, called Therapeutics for Rare and Neglected Diseases (TRND), marks the agency's largest foray into developing drugs. It will bring together expertise from various sectors of the NIH—including the Office of Rare Diseases Research (ORDR), the National Human Genome Research Institute, and the NIH Chemical Genomics Center (NCGC)—as well as expertise from outside researchers and organizations. TRND's focus will be moving candidate molecules through the preclinical phase of development and then licensing the candidates to other entities for further development.
Graphic Jump Location
Leishmaniasis, a disease spread by sand flies such as the one pictured above, may be among the rare or neglected diseases targeted by a new National Institutes of Health initiative.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 3
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.